Rockefeller Capital Management
CBIO icon

Rockefeller Capital Management’s Crescent Biopharma CBIO Stock Holding History

Rockefeller Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12
Closed -$3K – 3500
2021
Q1 		$3K Hold
12
– – ﹤0.01% 3019
2020
Q4 		$4K Buy
+12
New +$4.21K ﹤0.01% 2489

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's CBIO Position: Q2 2021 in Review

Rockefeller Capital Management sold out of Crescent Biopharma (CBIO) in Q2 2021, closing a stake of 12 shares — an estimated $3K sold.

Rockefeller Capital Management first reported a position in CBIO in Q4 2020 and held it in 2 quarters. The position peaked at $4K in Q4 2020. 58 funds tracked by Wall St. Rank hold CBIO as of Q2 2021.

  • Rockefeller Capital Management reported no remaining Crescent Biopharma position as of Q2 2021 after selling out during the quarter.
  • Rockefeller Capital Management sold 12 Crescent Biopharma shares in Q2 2021, an estimated $3K.
  • Rockefeller Capital Management first reported a position in Crescent Biopharma in Q4 2020 and held it in 2 quarters.
  • Rockefeller Capital Management's Crescent Biopharma position peaked at $4K in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2021.

Based on Rockefeller Capital Management's 13F filing for Q2 2021, filed 10 Aug 2021.